Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Three-day vaginal yeast infection drugs "most likely" future switches -- MD, PharmD survey.

This article was originally published in The Tan Sheet

Executive Summary

THREE-DAY YEAST INFECTION DRUGS LEAD LIST OF "MOST LIKELY" OTC SWITCHES in the next five years, according to a survey of physicians, pharmacists and consumers conducted by Fairfield, N.J.-based Kline & Co. Presenting some of the survey's findings at a May 17 session of an International Business Communications conference on Rx-to-OTC switches, Kline & Co. Healthcare Practice Manager Kathryn Greengrove Griffie noted that "the products that came out on top were...the three-day feminine yeast infection products." Prescription yeast infection remedies included in the survey were J&J's Monistat 3 and Terazole 3 and Bristol-Myers Squibb's Vagistat.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS083853

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel